Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Sims

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 11, 2026
Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trialLars L Raket, Ming Lu, Cynthia D Evans, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 22, 2021
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's diseaseJennifer A Zimmer, Sergey Shcherbinin, Michael D Devous, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug developmentGil D Rabinovici, Maria C Carrillo, Mark Forman, et al.
Nature Communications|April 5, 2020
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's diseaseShorena Janelidze, Erik Stomrud, Ruben Smith, et al.
The New England Journal of Medicine|July 17, 2023
Trial of Solanezumab in Preclinical Alzheimer's DiseaseReisa A Sperling, Michael C Donohue, Rema Raman, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 10, 2026
Infusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's diseasePaul Ardayfio, Garrett R Mullins, Rashna Khanna, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
Point of view: Challenges in implementation of new immunotherapies for Alzheimer's diseaseSandar Aye, Gunilla Johansson, Christoph Hock, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 22, 2012
Multicolored stain-free histopathology with coherent Raman imagingChristian W Freudiger, Rolf Pfannl, Daniel A Orringer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 13, 2020
Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's diseaseAlette M Wessels, Christopher Lines, Robert A Stern, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 2, 2025
Modified titration of donanemab reduces ARIA risk and maintains amyloid reductionHong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 11, 2026
Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trialLars L Raket, Ming Lu, Cynthia D Evans, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 22, 2021
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's diseaseJennifer A Zimmer, Sergey Shcherbinin, Michael D Devous, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug developmentGil D Rabinovici, Maria C Carrillo, Mark Forman, et al.
Nature Communications|April 5, 2020
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's diseaseShorena Janelidze, Erik Stomrud, Ruben Smith, et al.
The New England Journal of Medicine|July 17, 2023
Trial of Solanezumab in Preclinical Alzheimer's DiseaseReisa A Sperling, Michael C Donohue, Rema Raman, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 10, 2026
Infusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's diseasePaul Ardayfio, Garrett R Mullins, Rashna Khanna, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
Point of view: Challenges in implementation of new immunotherapies for Alzheimer's diseaseSandar Aye, Gunilla Johansson, Christoph Hock, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 22, 2012
Multicolored stain-free histopathology with coherent Raman imagingChristian W Freudiger, Rolf Pfannl, Daniel A Orringer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 13, 2020
Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's diseaseAlette M Wessels, Christopher Lines, Robert A Stern, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 2, 2025
Modified titration of donanemab reduces ARIA risk and maintains amyloid reductionHong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
Pageof 10